Get the Stockscreener App
141.87
1.20%
-1.73
After Hours:
141.87
Neurocrine Biosciences Inc stock is traded at $141.87, with a volume of 485.69K.
It is down -1.20% in the last 24 hours and up +10.07% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$143.60
Open:
$142.44
24h Volume:
485.69K
Relative Volume:
0.56
Market Cap:
$14.07B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.09
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-1.55%
1M Performance:
+10.07%
6M Performance:
+30.07%
1Y Performance:
+16.98%
1-Day Range:
$141.73
$144.04
1-Week Range:
$140.56
$145.16
52-Week Range:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.87 | 14.01B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Amundi Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Update - MarketBeat
Jacobs Levy Equity Management Inc. Grows Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teza Capital Management LLC - MarketBeat
Parkman Healthcare Partners LLC Buys 52,655 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Getting In Cheap On Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Might Be Difficult - 富途牛牛
United Services Automobile Association Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Alyeska Investment Group L.P. - MarketBeat
EFG Asset Management North America Corp. Has $1.12 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Baird Financial Group Inc. Buys 3,103 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Fibonacci Support Holding Strong in Neurocrine Biosciences Inc.July 2025 Trends & Weekly Chart Analysis and Guides - beatles.ru
Federation des caisses Desjardins du Quebec Lowers Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Palo Alto Investors LP Invests $1.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc. recovery potential after sell offJuly 2025 Momentum & Community Consensus Picks - Newser
Tick level data insight on Neurocrine Biosciences Inc. volatilityLong Setup & Entry Point Confirmation Signals - Newser
Canada Pension Plan Investment Board Raises Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is Neurocrine Biosciences Inc. benefiting from interest rate changesEarnings Overview Summary & Low Risk Entry Point Tips - خودرو بانک
Can Neurocrine Biosciences Inc. generate free cash flowJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - خودرو بانک
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Macro Moves & Safe Entry Momentum Tips - Newser
Neurocrine Biosciences: RBC Capital maintains Outperform, raises PT to $149. - AInvest
Neurocrine Bio. stock price target raised to $149 by RBC Capital - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating - MarketScreener
Armistice Capital LLC Acquires 108,190 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Summary & Reliable Intraday Trade Alerts - Newser
Will Neurocrine Biosciences Inc. benefit from current market trendsMarket Growth Review & Weekly Consistent Profit Watchlists - خودرو بانک
Will Neurocrine Biosciences Inc. price bounce be sustainable2025 Key Lessons & Long-Term Capital Growth Strategies - Newser
Is Neurocrine Biosciences Inc. a cyclical or defensive stockJuly 2025 Breakouts & Weekly Return Optimization Alerts - خودرو بانک
Will Neurocrine Biosciences Inc. stock go up soonJuly 2025 Volume & Community Consensus Picks - Newser
Neurocrine at Cantor Global Healthcare Conference: Strategic Insights on Growth - Investing.com Canada
Neurocrine Biosciences Inc. stock retracement – recovery analysis2025 Stock Rankings & AI Forecasted Stock Moves - Newser
What are Neurocrine Biosciences Inc.’s growth leversPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - خودرو بانک
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
Can Neurocrine Biosciences Inc. hit a new high this monthPortfolio Return Summary & Safe Capital Growth Stock Tips - Newser
Does Neurocrine Biosciences Inc. have pricing powerJuly 2025 Update & Fast Momentum Stock Entry Tips - خودرو بانک
Neurocrine Biosciences Shares Dip 4.09% on Strong Volume Surge to 478th Rank Amid Q2 Earnings Boost - AInvest
Neurocrine Biosciences' Strategic Position in the CNS Therapeutics Market - AInvest
Transcript : Neurocrine Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Does Neurocrine Biosciences Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - Newser
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com
What to expect from Neurocrine Biosciences Inc. in the next 30 daysJuly 2025 Final Week & Accurate Buy Signal Alerts - Newser
Is a relief rally coming for Neurocrine Biosciences Inc. holdersMarket Performance Recap & Breakout Confirmation Alerts - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropBull Run & Weekly Top Gainers Trade List - Newser
Risk vs reward if holding onto Neurocrine Biosciences Inc.July 2025 Volume & Trade Opportunity Analysis Reports - Newser
Custom watchlist performance reports with Neurocrine Biosciences Inc.Portfolio Profit Report & Real-Time Buy Zone Alerts - Newser
Kodai Capital Management LP Invests $9.51 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc. stock trendline breakdownIndex Update & Free Technical Confirmation Trade Alerts - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - Newser
Will Neurocrine Biosciences Inc. stock hit new highs in YEARQuarterly Market Review & Stock Market Timing Techniques - خودرو بانک
Is Neurocrine Biosciences Inc. showing signs of accumulation2025 Top Gainers & Fast Gaining Stock Reports - Newser
Is Neurocrine Biosciences Inc. being accumulated by smart moneyJuly 2025 Levels & Fast Entry and Exit Trade Plans - خودرو بانک
Technical Bounce Expected in Neurocrine Biosciences Inc. Next Week getLinesFromResByArray error: size == 0 - thegnnews.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):